Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14377195 | 0.82 | NEK2 (0.42) | NEK2L3MBTL1KDM4EGLACHRM2 | |
| SCHEMBL2516568 | 0.80 | — | — | |
| SCHEMBL22783783 | 0.80 | PTPN11 (0.34) | PTPN11FPR2 | |
| SCHEMBL20111958 | 0.80 | PTPN11 (0.34) | PTPN11FPR2 | |
| SCHEMBL25060592 | 0.79 | FPR2 (0.36) | KDM4EPTPN11FPR2 | |
| SCHEMBL22256985 | 0.79 | GRIN2D (0.36) | PTPN11CHRM2FPR2 | |
| SCHEMBL20007912 | 0.79 | CYP2D6 (0.36) | KDM4EPTPN11FPR2 | |
| SCHEMBL24535256 | 0.78 | USP2 (0.33) | NEK2 | |
| SCHEMBL20640397 | 0.76 | — | — | |
| SCHEMBL1382368 | 0.76 | POLB (0.32) | PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515916-B1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230125684-A1 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | CHEMOCENTRYX, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2023023534-A2 | ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-11529347-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210040150-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS | YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) | 2021-02-11 | — | — | US | disclosed |
| WO-2021026492-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS | Humanwell Pharmaceutical US (US) | 2021-02-11 | — | — | WO | disclosed |
| US-20200062760-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20190307745-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2019-10-10 | — | — | US | disclosed |
| WO-2018067615-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062760-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPRJ, PTPRC | NEK2 2583/4885L3MBTL1 3554/4885KDM4E 876/4885 |
| US-20190307745-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN21, PTPN5, PTPN1 | NEK2 936/4885L3MBTL1 2755/4885KDM4E 2017/4885 |
| US-11529347-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPN21, PTPN22, PTPN5 | NEK2 809/4885L3MBTL1 3477/4885KDM4E 2010/4885 |
| US-20230125684-A1 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | CCR6, CCR1, CCR3 | NEK2 3842/4885L3MBTL1 706/4885KDM4E 3778/4885 |
| US-20210040150-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS | OPRK1, OPRL1, OPRD1 | NEK2 4201/4885L3MBTL1 3421/4885KDM4E 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.